

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/606, 9/0 F
Source: IFI/6
Date Processed by STIC: 4/5/07

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

 TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.4.0 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
 U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street,
 Alexandria, VA 22314

Revised 01/10/06



Raw Sequence Listing Error Summary

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTY I Wrapped Aminos was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping." Linvalid Line Length The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping." Linvalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces. Misaligned Amino Numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead. Misaligned Amino Numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead. The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text. Sequence(s)	c
Wrapped Aminos Lovalid Line Length Wrapped Aminos Misaligned Amino Numbering Misaligned Amino Number Misaligned Amino Number Misaligned Amino Numbering Misaligned Amino Number Misaligned Amino Numbering Misaligned Amino Naminole factor As SCII (Do Not Misari Amino Andro Pilease Misaligned Amino Numbering Misaligned Amino Naminole factor As Sequence Nersean As Sequence Nersean As Sequence Normally Patenth would automatically generate this section to the missing. If intentional, please insert the follow	c
Misaligned Amino Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead. The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text. Sequence(s)	
Misaligned Amino Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead. The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text. Sequence(s)	
Sequence(s)	
each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the \$\leq 20 \rightarrow \cdot 223 \rightarrow section that some may be missing. A "bug" in PatentIn version 2.0 has caused the \$\leq 20 \rightarrow \cdot 223 \rightarrow section that some may be missing. A "bug" in PatentIn version 2.0 has caused the \$\leq 20 \rightarrow \cdot 223 \rightarrow section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant \$\leq 20 \rightarrow \cdot 220 \rightarrow \cdot 223 \rightarrow section to the subsequent amino acid sequences. Skipped Sequences (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (Xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences. Sequence(s) missing. If intentional, please insert the following lines for each skipped sequences. Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (NEW RULES) Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of \$\leq 220 \rightarrow \leq 223 \rightarrow in 's or Xaa's are present. In \$\leq 200\$ to \$\leq 223 \rightarrow section, please explain location of n or Xaa, and which residue n or Xaa represents.	
previously coded nucleic acid sequence. Please manually copy the relevant <200-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> section to the subsequences. 7 Skipped Sequences (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences. Sequence(s) missing. If intentional, please insert the following lines for each skipped sequences. Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence (NEW RULES) Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
(OLD RULES) (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences. Skipped Sequences (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence 210> sequence id number 30 Use of n's or Xaa's Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of 220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
8Skipped Sequence(s)missing. If intentional, please insert the following lines for each skipped sequence <210> sequence id number <400> sequence id number 000 Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
(NEW RULES) Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
10 Invalid C135 Per 1 203 - C0	
10 Invalid <213> Response	
IlUse of <220> Sequence(s)missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unkno Please explain source of genetic material in <220> to <223> section or use "chemically synthesized" as explanation. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32), also Sec. 1.823 of Sequence Rules	wn.'
Patentin 2.0 Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.	
13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid	

AMC - STIC Systems Branch - 03/02/06





IPW16

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/606,910F

DATE: 04/05/2007

TIME: 10:02:12

Input Set : A:\050185Sequence.txt

Output Set: N:\CRF4\04052007\1606910F.raw

```
3 <110> APPLICANT: Max-Delbrueck-Centrum fuer Molekulare Medizin
      5 <120> TITLE OF INVENTION: Tumor vaccines for mucl-positive carcinomas
      7 <130> FILE REFERENCE: 0107-027
C--> 9 <140> CURRENT APPLICATION NUMBER: US/09/606,910F
     10 <141> CURRENT FILING DATE: 2000-06-29
    12 <150> PRIOR APPLICATION NUMBER: DE 197 58 400.4
    13 <151> PRIOR FILING DATE: 1997-12-30
    15 <150> PRIOR APPLICATION NUMBER: PCT/DE98/03819
                                                          see M-2
    16 <151> PRIOR FILING DATE: 1998-12-30
    18 <160> NUMBER OF SEQ ID NOS: 6
    20 <170> SOFTWARE: PatentIn Ver. 2.1
```

ERRORED SEQUENCES

Does Not Comply Corrected Diskette Needed

```
22 <210> SEQ ID NO: 1
      23 <211> LENGTH: 7
      24 <212> TYPE: PRT
      25 <213> ORGANISM: human
      27 <220> FEATURE:
      28 <223> OTHER INFORMATION: immunodominant region of MUC1
      30 <400> SEQUENCE: 1
                                  misologied amino acid numbers (see item 3 on
Enor funnary
(1)
      31 Pro Asp Thr Arg Pro Ala Pro
 B--> 32 1
             5 خد
      34 <210> SEQ ID NO: 2
     35 <211> LENGTH: 8
     36 <212> TYPE: PRT
     37 <213> ORGANISM: mouse, IgG1
     39 <220> FEATURE:
     40 <223> OTHER INFORMATION: A76-A/C7 epitope
     42 <400> SEQUENCE: 2
     43 Ala Pro Asp Thr Arg Pro Ala Pro
44 1 5 musolgied numbers
B--> 44 1 _5-
     47 <210> SEQ ID NO: 3
     48 <211> LENGTH: 6
     49 <212> TYPE: PRT
     50 <213> ORGANISM: mouse, IgG1
     52 <220> FEATURE:
     53 <223> OTHER INFORMATION: MF06 epitope
     55 <400> SEQUENCE: 3
     56 Asp Thr Arg Pro Ala Pro
B--> 57 1 & 5
59 <210> SEQ ID NO: 4
```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/606,910F

DATE: 04/05/2007
TIME: 10:02:12

Input Set : A:\050185Sequence.txt
Output Set: N:\CRF4\04052007\I606910F.raw

```
60 <211> LENGTH: 21
      61 <212> TYPE: PRT
      62.<213> ORGANISM: Artificial Sequence
      64 <220> FEATURE:
      65 <223> OTHER INFORMATION: Description of Artificial Sequence: designed
               synthetical glycopeptide
      68 <400> SEQUENCE: 4
      69 Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser
 E--> 70 1 5 10 15 5
                                misabgred runkers
      72 Thr Ala Pro Pro Ala
 B--> 73
            <del>-20</del>-
                     20
      75 <210> SEQ ID NO: 5
      76 <211> LENGTH: 20
      77 <212> TYPE: PRT
      78 <213> ORGANISM: Artificial Sequence
      80 <220> FEATURE:
      81 <223> OTHER INFORMATION: Description of Artificial Sequence: designed
               synthetical glycopeptide
      84 <400> SEQUENCE: 5
     85 His Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr
B--> 86 1 <u>5 10 15</u> 5
     88 Ala Pro Pro Ala
                              mesalgred
B--> 89 -20-
                    م2
     93 <210> SEQ ID NO: 6
     94 <211> LENGTH: 7
     95 <212> TYPE: PRT
     96 <213> ORGANISM: human
     98 <220> FEATURE:
     99 <221> NAME/KEY: DOMAIN
     100 <222> LOCATION: (1) .. (7)
     101 <223> OTHER INFORMATION: immunodominant motif of the epithelial mucin (
              MUC1)
     102
     104 <400> SEQUENCE: 6
     105 Pro Asp Thr Arg Pro Ala Pro
B--> 106 1 5
                         5
```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/606,910F

DATE: 04/05/2007

TIME: 10:02:13

Input Set : A:\050185Sequence.txt
Output Set: N:\CRF4\04052007\1606910F.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number L:32 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:1 L:44 M:932 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:2 L:57 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:3 L:70 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:4 L:73 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:5 L:86 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:5 L:89 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:5 L:106 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:6

```
JUN 1 8 2007
```

Sequence Listing could not be accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: markspencer

Timestamp: Wed May 23 14:00:36 EDT 2007

Reviewer Comments:

<210> 2

<211> 8

<212> PRT

<213> mouse, IgG1

<220>

<223> A76-A/C7 epitope

<400> 2

Ala Pro Asp Thr Arg Pro Ala Pro

1

<210> 3

<211> 6

<212> PRT

<213> mouse, IgG1

<220>

<223> MF06 epitope

<400> 3

Asp Thr Arg Pro Ala Pro

1

5

Remove the ", IgG1" from the response for numeric identifier <213> in SEQ ID # 2 and 3.

For SEQ ID # 1, 2, and 3 add numeric identiers <221> and <222> to the feature.
